Serina Therapeutics, Inc. filed a Certificate of Elimination with the Delaware Secretary of State on October 5, 2026, removing the specific designation for its Series A Convertible Preferred Stock. The move formally erases the terms previously attached to that class of shares from the company's First Amended and Restated Certificate of Incorporation.
The filing, reported on Form 8-K, cites Section 151(g) of the Delaware General Corporation Law. It targets the Certificate of Designations of Preferences, Rights and Limitations originally filed on April 10, 2025, and corrected on May 22, 2025. By eliminating these matters, Serina Therapeutics resets the status of the shares previously designated as Series A Preferred Stock.
No shares of the Series A Preferred Stock remain outstanding. All issued and outstanding shares of this class have already been converted into shares of the company's common stock. Consequently, no new shares will be issued subject to the old Certificate of Designations.
Upon filing, the former Series A Preferred Stock became authorized but unissued preferred stock without any series designation. The company's common stock, which carries a par value of $0.0001 per share, continues to trade under the symbol SER on NYSE American.
Serina Therapeutics is headquartered at 601 Genome Way, Suite 2001 in Huntsville, Alabama. The company is incorporated in Delaware and is identified by Commission File Number 1-38519 and IRS Employer Identification Number 82-1436829. The Form 8-K was signed by Steve Ledger, Chief Executive Officer, on October 9, 2026.
The filing includes a copy of the Certificate of Elimination as Exhibit 3.1. The description provided in the report does not purport to be complete and is qualified by reference to the full text of that exhibit.